1. Home
  2. |Insights
  3. |Government Contracts Mergers & Acquisitions in 2017: Challenges and Opportunities on the Horizon

Government Contracts Mergers & Acquisitions in 2017: Challenges and Opportunities on the Horizon

Client Alert | less than 1 min read | 06.26.17

Please join us on June 27, 2017, 12:00pm-1:30pm for a lunchtime panel discussion regarding “Government Contracts M&A in 2017: Challenges and Opportunities on the Horizon.” A panel of industry, private equity, and law firm representatives will tackle key considerations for buyers and sellers to take into account when structuring and executing M&A transactions in the government contract marketplace, including: due diligence “hot spots” and effective risk management; specific considerations regarding transactions involving for foreign entities; and unique requirements when acquiring or selling companies in the defense and intelligence fields. For more information, click here.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights